Predicine to Introduce PredicineALERT™ MRD Assay and Present Twelve Posters at AACR 2023 Conference
14 avr. 2023 16h47 HE
|
Predicine
HAYWARD, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present data from 12 studies and introduce PredicineALERT™, a...
Predicine to Present Four Studies at 2023 ASCO Genitourinary (GU) Symposium Highlighting the Technical and Clinical Utility of Predicine’s Liquid Biopsy Based Assays
16 févr. 2023 16h05 HE
|
Predicine
HAYWARD, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, is committed to advancing genitourinary (GU) cancer detection and treatment decisions through its...
Predicine to Introduce PredicineCOMPLETE™, its Genome-Wide Liquid Biopsy Solution, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
10 nov. 2022 21h00 HE
|
Predicine
SILICON VALLEY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announces the introduction of PredicineCOMPLETE™, the organization’s most comprehensive...
Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration
20 sept. 2022 09h00 HE
|
Predicine
HAYWARD, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced...
Predicine to Present New Data at ESMO 2022 Demonstrating the Utility of its Portfolio of Liquid Biopsy Tests for Cancer Patients
08 sept. 2022 16h00 HE
|
Predicine
SILICON VALLEY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, announced today that it will present four posters at the ESMO conference being held...
Predicine Expands to Europe with the recently launched CE-Marked cfDNA Assay PredicineCARE™ for Genomic Profiling in Blood and Urine
09 août 2022 08h00 HE
|
Predicine
SILICON VALLEY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE™ for genomic profiling in blood and urine....
Predicine Expands Its Nationwide COVID-19 Testing Capability Through the Recent FDA EUA Authorization of Predicine SARS-CoV-2 RT-PCR Test and Self-Collection Kit
25 juil. 2022 08h00 HE
|
Predicine
SILICON VALLEY, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced...